| Similar Articles |
|---|
 |
Reason
April 2008
Jacob Sullum |
No Bad Drugs Two books on drug use in America offer conflicting opinions and further emphasize the arbitrary distinctions at the root of drug prohibition.   |
Chemistry World
June 26, 2013
Emma Stoye |
UN report warns of global rise in legal highs The latest World Drug Report from the United Nations Office on Drugs and Crime says governments around the world are struggling to cope with a growing number of legal party drugs. |
Search Engine Watch
May 18, 2010
Matthew Ncube |
Tracking Search Habits: The Mephedrone Ban Are Brits kicking the habit, or on the verge of getting hooked? Drilling down to see what the search data tells us. |
Chemistry World
June 3, 2015
Katrina Kramer |
Drugged: the science and culture behind psychotropic drugs Richard Miller, a pharmacology researcher at Northwestern University, US, and a medical humanities and bioethics professor, has written his first popular science book on the chemistry and culture of psychoactive compounds. |
Chemistry World
June 12, 2013
Maria Burke |
'Scientific censorship' hamstringing psychoactive drug research Legal controls on psychoactive drugs have hindered neuroscience research and the discovery of new treatments for brain disorders in 'one of the most scandalous examples of scientific censorship in modern times', claim researchers. |
Chemistry World
March 23, 2010 |
Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann |
Chemistry World
November 1, 2012
Andrew Turley |
Novartis biotech plant for Singapore The new plant, which will make drugs through cell culture, will be located with the Novartis production plant at Tuas. |
Chemistry World
June 24, 2015
Patrick Walter |
Legal in theory Governments around the world are faced with the particularly tricky problem of what they should do about 'legal highs'. |
Reason
October 2004
Michael Erard |
Open Secrets How the U.S. government lost the drug war in cyberspace. |
Reason
March 2009
Mike Riggs |
High Art An interview with David Hillman, whose new book The Chemical Muse: Drug Use and the Roots of Western Civilization examines the role of recreational drug use in antiquity. |
Wired
April 24, 2007
David Ewing Duncan |
Down With Happiness Drugs. Implants. Virtual reality. Do we really want joy 24/7? |
Reason
June 2005
Toby Muse |
Legalize Now! War-weary Colombia--and its Conservative Party--consider ending the drug war. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
Reason
April 2004
Joli Jensen |
Emotional Choices What story you choose to believe about antidepressants reveals a deeper truth about who you are. |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
Reason
October 2005
Maia Szalavitz |
In Defense of Happy Pills While psychotherapy validated by research has its place, there is no convincing reason why it should be considered inherently superior to drugs. Pleasure can be just as important for emotional recovery and growth as pain, if not more so. |
Chemistry World
June 4, 2013
Maria Burke |
'Legal high' production gathers pace New designer drugs are popping up in Europe at an unprecedented rate, sometimes on the illicit drug market and sometimes as 'legal' alternatives to controlled drugs, according to the latest report by the EU drugs agency. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
AskMen.com
March 18, 2015
Gonzo Nieto |
The Health Benefits Of Psychedelic Drugs As weed becomes more accepted, are psychedelic drugs next? Here's why you should take LSD seriously. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
February 21, 2008
Brian Lawler |
A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
Chemistry World
April 30, 2014
Emma Stoye |
New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
AskMen.com
Dustin Driver |
Drug Testing 101 A look at how drug tests work. This article debunks some common drug testing rumors and discusses the legal meds that can raise alarm bells in the testing lab. |
Chemistry World
May 9, 2011
Sarah Houlton |
Ecstasy substitute poses major health risks Scientists at Anglia Ruskin University haves shown that one of the most common 'legal high' designer drugs, benzylpiperazine, is not only dangerous when it's taken - repeated consumption poses major health risks. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
June 16, 2009
Brian Orelli |
Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
October 18, 2010
Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
